pCOM-CD63-4xM12-COM
(Plasmid
#138351)
-
PurposeExpressing COM-CD63-4xM12-COM fusion protein in mammalian cells
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 138351 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneCD63-pEGFP C2
-
Backbone manufacturerAddgene 62964
- Backbone size w/o insert (bp) 3937
- Total vector size (bp) 5351
-
Vector typeMammalian Expression, Lentiviral, CRISPR
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameCOM-CD63-4xM12-COM fusion protein
-
SpeciesHuman and bacteriophage
-
Insert Size (bp)1404
-
Tag
/ Fusion Protein
- COM-CD63-4xM12-COM, four copies of muscle homing M12 peptide is inserted into the extramembrane loop of CD63
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byAddgene 62964 CD63-pEGFP C2
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
The insert sequence can be unstable during bacterial propagation. Restriction digests should be used to verify the full-length plasmid is present.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pCOM-CD63-4xM12-COM was a gift from Baisong Lu (Addgene plasmid # 138351) -
For your References section:
Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing. Yao X, Lyu P, Yoo K, Yadav MK, Singh R, Atala A, Lu B. J Extracell Vesicles. 2021 Mar;10(5):e12076. doi: 10.1002/jev2.12076. Epub 2021 Mar 16. 10.1002/jev2.12076 PubMed 33747370